Werewolf Therapeutics Q2 FY26 swings to net income of $3.7 million; revenue rises to $21 million
HOWL•Expenses and liquidity
GAAP R&D expense fell 52.84% to $6.2 million, while GAAP G&A expense climbed 74.57% to $7.7 million.
Cash and cash equivalents dropped to $22 million as of June 30, from $46.5 million as of March 31; runway forecast into Q2 2027.
Debt repayment and outlook
Werewolf repaid all amounts owed under its K2 loan agreement; CEO Daniel J. Hicklin expects H2 updates on strategic alternatives and WTX-124/WTX-330 data.
Q2 results swing to profit on higher collaboration revenue
Werewolf Therapeutics swung to GAAP net income of $3.7 million, from a GAAP net loss of $18 million a year earlier.
GAAP collaboration revenue rose to $21 million, driven by revenue recognized from the sale of its JZP898 program to Jazz.
